170 related articles for article (PubMed ID: 30166585)
1. Application of the fragment molecular orbital method to discover novel natural products for prion disease.
Choi J; Kim HJ; Jin X; Lim H; Kim S; Roh IS; Kang HE; No KT; Sohn HJ
Sci Rep; 2018 Aug; 8(1):13063. PubMed ID: 30166585
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.
Hyeon JW; Choi J; Kim SY; Govindaraj RG; Jam Hwang K; Lee YS; An SS; Lee MK; Joung JY; No KT; Lee J
Sci Rep; 2015 Oct; 5():14944. PubMed ID: 26449325
[TBL] [Abstract][Full Text] [Related]
3. In silico strategies on prion pathogenic conversion and inhibition from PrP
Pagadala NS; Syed K; Bhat R
Expert Opin Drug Discov; 2017 Mar; 12(3):241-248. PubMed ID: 28118747
[TBL] [Abstract][Full Text] [Related]
4. Novel Compounds Identified by Structure-Based Prion Disease Drug Discovery Using In Silico Screening Delay the Progression of an Illness in Prion-Infected Mice.
Ishibashi D; Ishikawa T; Mizuta S; Tange H; Nakagaki T; Hamada T; Nishida N
Neurotherapeutics; 2020 Oct; 17(4):1836-1849. PubMed ID: 32767031
[TBL] [Abstract][Full Text] [Related]
5. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
Hosokawa-Muto J; Kamatari YO; Nakamura HK; Kuwata K
Antimicrob Agents Chemother; 2009 Feb; 53(2):765-71. PubMed ID: 19015328
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2-aminothiazoles as potent antiprion compounds.
Ghaemmaghami S; May BC; Renslo AR; Prusiner SB
J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192
[TBL] [Abstract][Full Text] [Related]
7. Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods.
Li L; Wei W; Jia WJ; Zhu Y; Zhang Y; Chen JH; Tian J; Liu H; He YX; Yao X
J Comput Aided Mol Des; 2017 Dec; 31(12):1053-1062. PubMed ID: 29159521
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Drug Discovery for Prion Disease Using a Novel Binding Simulation.
Ishibashi D; Nakagaki T; Ishikawa T; Atarashi R; Watanabe K; Cruz FA; Hamada T; Nishida N
EBioMedicine; 2016 Jul; 9():238-249. PubMed ID: 27333028
[TBL] [Abstract][Full Text] [Related]
9. Thienyl pyrimidine derivatives with PrP(Sc) oligomer-inducing activity are a promising tool to study prions.
Imberdis T; Ayrolles-Torro A; Verdier JM; Perrier V
Curr Top Med Chem; 2013; 13(19):2477-83. PubMed ID: 24059332
[TBL] [Abstract][Full Text] [Related]
10. A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.
Ferreira NC; Ascari LM; Hughson AG; Cavalheiro GR; Góes CF; Fernandes PN; Hollister JR; da Conceição RA; Silva DS; Souza AMT; Barbosa MLC; Lara FA; Martins RAP; Caughey B; Cordeiro Y
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133563
[TBL] [Abstract][Full Text] [Related]
11. In silico studies and fluorescence binding assays of potential anti-prion compounds reveal an important binding site for prion inhibition from PrP(C) to PrP(Sc).
Pagadala NS; Perez-Pineiro R; Wishart DS; Tuszynski JA
Eur J Med Chem; 2015 Feb; 91():118-31. PubMed ID: 25042003
[TBL] [Abstract][Full Text] [Related]
12. Molecular Dynamics Simulation Study on the Binding and Stabilization Mechanism of Antiprion Compounds to the "Hot Spot" Region of PrP
Zhou S; Liu X; An X; Yao X; Liu H
ACS Chem Neurosci; 2017 Nov; 8(11):2446-2456. PubMed ID: 28795797
[TBL] [Abstract][Full Text] [Related]
13. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.
Karapetyan YE; Sferrazza GF; Zhou M; Ottenberg G; Spicer T; Chase P; Fallahi M; Hodder P; Weissmann C; Lasmézas CI
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):7044-9. PubMed ID: 23576755
[TBL] [Abstract][Full Text] [Related]
14. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
[TBL] [Abstract][Full Text] [Related]
15. Identification of Anti-prion Compounds using a Novel Cellular Assay.
Imberdis T; Heeres JT; Yueh H; Fang C; Zhen J; Rich CB; Glicksman M; Beeler AB; Harris DA
J Biol Chem; 2016 Dec; 291(50):26164-26176. PubMed ID: 27803163
[TBL] [Abstract][Full Text] [Related]
16. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel fluorescent probes preventing PrP
Zaccagnini L; Brogi S; Brindisi M; Gemma S; Chemi G; Legname G; Campiani G; Butini S
Eur J Med Chem; 2017 Feb; 127():859-873. PubMed ID: 27842893
[TBL] [Abstract][Full Text] [Related]
18. The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrP
Pagadala NS; Bjorndahl TC; Joyce M; Wishart DS; Syed K; Landi A
Bioorg Med Chem; 2017 Oct; 25(20):5875-5888. PubMed ID: 28951092
[TBL] [Abstract][Full Text] [Related]
19. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets.
Poncet-Montange G; St Martin SJ; Bogatova OV; Prusiner SB; Shoichet BK; Ghaemmaghami S
J Biol Chem; 2011 Aug; 286(31):27718-28. PubMed ID: 21610081
[TBL] [Abstract][Full Text] [Related]
20. Transition of the prion protein from a structured cellular form (PrP
Baral PK; Yin J; Aguzzi A; James MNG
Protein Sci; 2019 Dec; 28(12):2055-2063. PubMed ID: 31583788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
